Huaxun Wu | Toxicology and Pharmaceutical Science | Outstanding Contribution Award

Published on by Research Awards

Dr. Huaxun Wu | Toxicology and Pharmaceutical Science | Outstanding Contribution Award

Anhui Medical University | China

Dr. Huaxun Wu is an accomplished pharmacologist and Associate Professor at Anhui Medical University, serving as a Master’s Supervisor with a strong record of academic leadership, research excellence, and translational impact in anti-inflammatory immunopharmacology and clinical pharmacology. He holds both MD and PhD degrees in Pharmacology and has established himself as a recognized contributor to pharmacological science through sustained competitive funding, high-quality publications, and active service within national and provincial academic societies. Dr. Wu has served as Principal Investigator for multiple prestigious research programs, including the National Natural Science Foundation of China (Youth Program), the Anhui Provincial Natural Science Foundation (General Program), the Anhui Provincial Key Program for Outstanding Young Talents in Universities, and the Anhui Provincial Key Program for Natural Science Research in Higher Education Institutions. These projects focus on the mechanisms of inflammation, immune regulation, and pharmacological intervention, contributing to improved understanding of drug targets and therapeutic strategies in inflammatory and immune-related diseases. With more than 30 peer-reviewed academic publications, including over 20 SCI-indexed articles, Dr. Wu’s work has achieved significant international visibility, reflected in more than 1,183 citing articles. His research demonstrates a strong balance between fundamental pharmacological discovery and methodological rigor. In addition to journal publications, he has contributed substantially to pharmacological education and research methodology through the publication of authoritative textbooks, including Pharmacological Experimental Methodology (4th Edition) and Pharmacological Research Methodology, which are widely used in academic and clinical training. Dr. Wu’s innovation capacity is further evidenced by his intellectual property portfolio, which includes one granted national patent and three granted PCT patents, underscoring the translational potential and practical relevance of his research outputs. His editorial involvement with the Chinese Pharmacology Bulletin reflects peer recognition of his expertise and commitment to maintaining high scientific standards.

Citation Metrics (Scopus)

2000
1000
500
400
300
200
100
50
30
10
0

Citations
1784

Documents
76

h-index
28

Citations

h-index

i10-index

View Scopus Profile

Featured Publications

EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Published on by Research Awards

Dr. EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Clinical pharmacy resident at Tehran University of Medical Sciences, Iran.

Dr. Emad Molaei is a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences/Imam Khomeini Hospital Complex. With a PharmD from Mashhad University of Medical Sciences and a current residency in Pharmacotherapy, he has a strong foundation in clinical pharmacy. His research focuses on nephroprotective activity, cardiovascular diseases, and COVID-19 treatments, with several first-author publications in renowned journals. Dr. Molaei’s professional experience includes roles as a community pharmacist, medication consultant, and pharmacotherapy interventionist in various hospitals. He is also the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company. Recognized for his academic excellence, he has received multiple awards and honors, including being the top-ranked graduate and outstanding student at each academic level. Dr. Molaei is skilled in data analysis, scientific writing, and project management, contributing significantly to his field.

Professional Profiles:

Education 🎓

🎓 Emad Molaei is currently pursuing his Pharmacotherapy (Clinical Pharmacy) residency at the School of Pharmacy, Tehran University of Medical Sciences (TUMS), since September 2021. He completed his Pharm-D at the School of Pharmacy, Mashhad University of Medical Sciences (MUMS) in September 2021, achieving a commendable total average of 18.00. Prior to that, he earned his Diploma of Science from the Gifted Program in the National Organization for Development, with an impressive total average of 19.46 in September 2015.

Professional Experience

👨‍⚕️ Emad Molaei’s professional journey includes his current role as a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences / Imam Khomeini Hospital Complex. He has extensive clinical experience as a Community Pharmacist at 13-Aban TUMS Community Chain Pharmacy in Tehran and Razavi Pharmaceutical Service Institute in Mashhad. Additionally, he has served as a Medication Consultant at the Drug and Poison Information Center (DPIC) in Tehran and has been involved in pharmacotherapy interventions at several hospitals, including Imam Khomeini, Shariati, Sina, and Roozbeh Hospitals in Tehran. Emad also has experience working in the satellite pharmacy of the critical care department at Sina Hospital and initiated activities in the clean room dedicated to cytotoxic drug production at the Cancer Institute, Imam Khomeini Hospital Complex. Beyond his clinical roles, he has contributed as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology.

Research Interest

🔬 Emad Molaei’s research interests span across various aspects of clinical pharmacy and pharmacotherapy. He is particularly focused on the nephroprotective activity of natural products against chemical toxicants and the role of the Nrf2/ARE signaling pathway. Emad also investigates the therapeutic potential of Resolvin D1 in Acute Respiratory Distress Syndrome and explores emerging therapeutic targets for cardiovascular diseases, including the LKB1 pathway and the Mas receptor. Additionally, he is involved in clinical studies evaluating the efficacy and safety of treatments for burn patients, such as silver sulfadiazine 1%-cerium nitrate 2.2% cream. Emad’s work also extends to the treatment of COVID-19 with Remdesivir in special populations, showcasing his commitment to addressing critical health issues through innovative research.

Award and Honors

🏆 Emad Molaei has received numerous awards and honors throughout his academic and professional career. He was recognized as the most outstanding student at each academic level and graduated as the top-ranked student from the Mashhad Faculty of Pharmacy. Emad also achieved the highest rank in the pharmacy specialty examination and is a member of the Brilliant Academic Talent Program. His presentation skills have been acknowledged with the best poster award at the 12th subspecialty congress of Iranian burn physicians. Emad’s dedication to excellence is further demonstrated by his active membership in various professional organizations and his role as the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company.

Research Skills

🧪 Emad Molaei possesses a robust set of research skills. He is proficient in data analysis using software such as SPSS, GraphPad Prism, and Sigma Plot. His scientific writing abilities are well-honed, and he is adept with EndNote and Microsoft Office tools. Emad’s project management skills are complemented by his experience as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology. His clinical research experience includes participation in multiple clinical trials and studies, showcasing his ability to handle complex research projects effectively.

Publications by Emad Molaei

  1. Remdesivir: Treatment of COVID-19 in Special Populations
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • Year: 2024
    • Citations: 1
  2. Mas Receptor: A Potential Strategy in the Management of Ischemic Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Hayes, A.W., Karimi, G.
    • Journal: Cell Cycle
    • Year: 2023
    • Citations: 5
  3. LKB1: An Emerging Therapeutic Target for Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Sadeghnia, H., Hayes, A.W., Karimi, G.
    • Journal: Life Sciences
    • Year: 2022
    • Citations: 13
  4. Resolvin D1: Therapeutic Target in Acute Respiratory Distress Syndrome
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: European Journal of Pharmacology
    • Year: 2021
    • Citations: 18
  5. Nephroprotective Activity of Natural Products Against Chemical Toxicants: The Role of Nrf2/ARE Signaling Pathway
    • Authors: Molaei, E., Molaei, A., Abedi, F., Hayes, A.W., Karimi, G.
    • Journal: Food Science and Nutrition
    • Year: 2021
    • Citations: 23